Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection

References

  1. 1.

    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Hepatitis C Intervention Therapy Group: Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567, 2000

    CAS  Article  Google Scholar 

  2. 2.

    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, International Hepatitis Interventional Therapy Group: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–965, 2001

    CAS  Article  Google Scholar 

  3. 3.

    Sonnenblick M, Rosin AJ: Cardiotoxicity of interferon: A review of 44 cases. Chest 99:557–561, 1991

    CAS  Article  Google Scholar 

  4. 4.

    Conlon KC, Urba WJ, Smith JW2nd, Steis RG, Longo DL, Clark JW: Exacerbation of symptoms of autoimmune disease in patients receiving alphainterferon therapy. Cancer 65:2237–2242, 1990

    CAS  Article  Google Scholar 

  5. 5.

    Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K: Pneumonitis associated with natural and recombinant Interferon Alfa therapy for chronic hepatitis C. Chest 105:939–941, 1994

    CAS  Article  Google Scholar 

  6. 6.

    Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M: Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696, 1996

    CAS  Article  Google Scholar 

  7. 7.

    Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK: Pegylated interferon and ribavirin induced interstitial pneumonitis with ARDS. Chest 124:406–410, 2003.

    Article  Google Scholar 

  8. 8.

    Ogata K, Koga T, Yagawa K: Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 106:612–613, 1994

    CAS  Article  Google Scholar 

  9. 9.

    Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, Cagatay T, Yilmazabayhan D, Senturk H: Sarcoidosis after use of interferon for chronic hepatitis C. Dig Dis Sci 48:169–173, 2003

    CAS  Article  Google Scholar 

  10. 10.

    Bini EJ, Weinshel EH: Severe exacerbation of Asthma: A new side effect of interferon-α in patients with Asthma and chronic hepatitis C. Mayo Clin Proc 74:367–370, 1994

    Article  Google Scholar 

  11. 11.

    Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The META VIR Cooperative Study Group. Hepatology 24:289–293, 1996

    CAS  Article  Google Scholar 

  12. 12.

    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo controlled study. J Hepatol 25:591–598, 1996

    CAS  Article  Google Scholar 

  13. 13.

    Abbas AK, Lichtman AH, Pober JS (eds): Effector mechanism of immune responses. In: Cellular and Molecular Immunology. Philadelphia, Saunders, pp 235–335, 2000

    Google Scholar 

  14. 14.

    Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, Watanabe J, Miyamoto T, Ito K: Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146:266–268, 1992

    CAS  Article  Google Scholar 

  15. 15.

    Irving WL, Day S, Johnston ID: Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 148:1683–1684, 1993

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Peter Schenk.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fuhrmann, V., Kramer, L., Bauer, E. et al. Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection. Dig Dis Sci 49, 1966–1970 (2004). https://doi.org/10.1007/s10620-004-9602-3

Download citation

  • peginterferon α
  • ribavirin
  • hepatitis C
  • interstitial pneumonitis
  • pulmonary toxicity
  • side effect